Developing Probiotics as Food and Drugs: Scientific and Regulatory ChallengesHIBBERD, Patricia L; HOFFMAN, Freddie Ann; HEIMBACH, James T et al.Clinical infectious diseases. 2008, Vol 46, issn 1058-4838, 101 p., SUP2Conference Proceedings

Mechanisms of Action of ProbioticsWALKER, W. Allan.Clinical infectious diseases. 2008, Vol 46, issn 1058-4838, S87-S91, SUP2Conference Paper

Probiotics in the United StatesVANDERHOOF, Jon A; YOUNG, Rosemary.Clinical infectious diseases. 2008, Vol 46, issn 1058-4838, S67-S72, SUP2Conference Paper

The Safety of ProbioticsSNYDMAN, David R.Clinical infectious diseases. 2008, Vol 46, issn 1058-4838, S104-S111, SUP2Conference Paper

Current Marketplace for Probiotics : A Japanese PerspectiveAMAGASE, Harunobu.Clinical infectious diseases. 2008, Vol 46, issn 1058-4838, S73-S75, SUP2Conference Paper

Environmental Assessment Requirements for Live Biological DrugsSUTTON, Ann.Clinical infectious diseases. 2008, Vol 46, issn 1058-4838, S112-S114, SUP2Conference Paper

Impact of the Intestinal Microbiota on the Development of Mucosal DefenseGASKINS, H. Rex; CROIX, Jennifer A; NAKAMURA, Noriko et al.Clinical infectious diseases. 2008, Vol 46, issn 1058-4838, S80-S86, SUP2Conference Paper

Probiotics : Definition, Sources, Selection, and UsesSANDERS, Mary Ellen.Clinical infectious diseases. 2008, Vol 46, issn 1058-4838, S58-S61, SUP2Conference Paper

Business Considerations in the Development of ProbioticsHOFFMAN, Freddie Ann.Clinical infectious diseases. 2008, Vol 46, issn 1058-4838, S141-S143, SUP2Conference Paper

The US Food and Drug Administration and Probiotics : Regulatory CategorizationDEGNAN, Frederick H.Clinical infectious diseases. 2008, Vol 46, issn 1058-4838, S133-S136, SUP2Conference Paper

Health-Benefit Claims for Probiotic ProductsHEIMBACH, James T.Clinical infectious diseases. 2008, Vol 46, issn 1058-4838, S122-S124, SUP2Conference Paper

Development of Probiotics as Biologic DrugsHOFFMAN, Freddie Ann.Clinical infectious diseases. 2008, Vol 46, issn 1058-4838, S125-S127, SUP2Conference Paper

Product Development of Probiotics as Biological DrugsSUTTON, Ann.Clinical infectious diseases. 2008, Vol 46, issn 1058-4838, S128-S132, SUP2Conference Paper

Clinical Indications for Probiotics : An OverviewGOLDIN, B. R; GORBACH, S. L.Clinical infectious diseases. 2008, Vol 46, issn 1058-4838, S96-S100, SUP2Conference Paper

Clinical Research on Probiotics : The Interface between Science and RegulationTAMAYO, Carmen.Clinical infectious diseases. 2008, Vol 46, issn 1058-4838, S101-S103, SUP2Conference Paper

How Science Will Help Shape Future Clinical Applications of ProbioticsREID, Gregor.Clinical infectious diseases. 2008, Vol 46, issn 1058-4838, S62-S66, SUP2Conference Paper

Probiotic Foods and Drugs : Impact of US Regulatory Status on Design of Clinical TrialsHIBBERD, Patricia L; DAVIDSON, Lisa.Clinical infectious diseases. 2008, Vol 46, issn 1058-4838, S137-S140, SUP2Conference Paper

Role of Probiotics Stakeholders in Future Research and Policy on Probiotics Use in the United StatesKLEIN, Marguerite; DWYER, Johanna.Clinical infectious diseases. 2008, Vol 46, issn 1058-4838, S144-S151, SUP2Conference Paper

Preclinical Testing in the Development of Probiotics : A Regulatory Perspective with Bacillus Strains as an ExampleSOROKULOVA, Iryna.Clinical infectious diseases. 2008, Vol 46, issn 1058-4838, S92-S95, SUP2Conference Paper

Probiotic Formulations and Applications, the Current Probiotics Market, and Changes in the Marketplace : A European PerspectiveSAXELIN, Maija.Clinical infectious diseases. 2008, Vol 46, issn 1058-4838, S76-S79, SUP2Conference Paper

Regulation of Probiotic Substances as Ingredients in Foods : Premarket Approval or Generally Recognized as Safe NotificationMATTIA, Antonia; MERKER, Robert.Clinical infectious diseases. 2008, Vol 46, issn 1058-4838, S115-S118, SUP2Conference Paper

US Food and Drug Administration Regulations Governing Label Claims for Food Products, Including ProbioticsSALDANHA, Leila G.Clinical infectious diseases. 2008, Vol 46, issn 1058-4838, S119-S121, SUP2Conference Paper